The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Veldoreotide (Primary) ; Octreotide
- Indications Acromegaly
- Focus Therapeutic Use
- Sponsors Aspireo Pharmaceuticals
- 05 Feb 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 30 Apr 2014 New trial record
- 03 Apr 2013 Results reported in an Aspireo Pharmaceuticals media release.